EGFR and neoplasm: A phase II multicenter study also showed that tumor genomic mutations TP53 and RBM10 were the most frequently co-occurring with EGFR mutations [26], We found from The Cancer Genome Atlas (TCGA) that approximately 8.1% of EGFR-mutated LUAD patients harbor RBM10 mutations (Fig. 1A).